Terms: = Pancreatic cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
25 results:
1. Response of Locally Advanced pancreatic cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and clinical outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract] [Full Text] [Related]
2. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract] [Full Text] [Related]
3. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract] [Full Text] [Related]
4. β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of pancreatic Adenocarcinoma.
Lenggenhager D; Bengs S; Fritsch R; Hussung S; Busenhart P; Endhardt K; Töpfer A; The FO; Bütikofer S; Gubler C; Scharl M; Morell B
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00395. PubMed ID: 34388137
[TBL] [Abstract] [Full Text] [Related]
5. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract] [Full Text] [Related]
6. Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Davis K; Dunseth CD; Mott SL; Cramer-Morales KL; Miller AM; Ear PH; Mezhir JJ; Bellizzi AM; Chan CHF
PLoS One; 2019; 14(3):e0213576. PubMed ID: 30856230
[TBL] [Abstract] [Full Text] [Related]
7. clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
[TBL] [Abstract] [Full Text] [Related]
8. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma.
Pak LM; Schattner MA; Balachandran V; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
HPB (Oxford); 2018 Feb; 20(2):182-187. PubMed ID: 29033025
[TBL] [Abstract] [Full Text] [Related]
9. Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers.
Luo Z; Li Y; Zuo M; Liu C; Tian W; Yan D; Wang H; Li D
Mol Carcinog; 2017 May; 56(5):1438-1448. PubMed ID: 27996162
[TBL] [Abstract] [Full Text] [Related]
10. Single-centre experience of extending indications for percutaneous intraportal islet autotransplantation (PIPIAT) after pancreatic surgery to prevent diabetes: feasibility, radiological aspects, complications and clinical outcome.
Venturini M; Sallemi C; Colantoni C; Agostini G; Balzano G; Esposito A; Secchi A; De Cobelli F; Falconi M; Piemonti L; Maffi P; Del Maschio A
Br J Radiol; 2016 Aug; 89(1064):20160246. PubMed ID: 27327404
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
[TBL] [Abstract] [Full Text] [Related]
12. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.
Connolly D; Hoang HG; Adler E; Tazearslan C; Simmons N; Bernard VV; Castaldi M; Oktay MH; Montagna C
Biol Chem; 2014 Feb; 395(2):157-67. PubMed ID: 24127542
[TBL] [Abstract] [Full Text] [Related]
13. The clinical impact of uncertainties in the mean excitation energy of human tissues during proton therapy.
Besemer A; Paganetti H; Bednarz B
Phys Med Biol; 2013 Feb; 58(4):887-902. PubMed ID: 23337713
[TBL] [Abstract] [Full Text] [Related]
14. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Mizuma M; Rasheed ZA; Yabuuchi S; Omura N; Campbell NR; de Wilde RF; De Oliveira E; Zhang Q; Puig O; Matsui W; Hidalgo M; Maitra A; Rajeshkumar NV
Mol Cancer Ther; 2012 Sep; 11(9):1999-2009. PubMed ID: 22752426
[TBL] [Abstract] [Full Text] [Related]
15. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.
Streppel MM; Vincent A; Mukherjee R; Campbell NR; Chen SH; Konstantopoulos K; Goggins MG; Van Seuningen I; Maitra A; Montgomery EA
Hum Pathol; 2012 Oct; 43(10):1755-63. PubMed ID: 22542127
[TBL] [Abstract] [Full Text] [Related]
16. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract] [Full Text] [Related]
17. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract] [Full Text] [Related]
18. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Manuyakorn A; Paulus R; Farrell J; Dawson NA; Tze S; Cheung-Lau G; Hines OJ; Reber H; Seligson DB; Horvath S; Kurdistani SK; Guha C; Dawson DW
J Clin Oncol; 2010 Mar; 28(8):1358-65. PubMed ID: 20142597
[TBL] [Abstract] [Full Text] [Related]
19. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
Dong X; Jiao L; Li Y; Evans DB; Wang H; Hess KR; Abbruzzese JL; Li D
J Clin Oncol; 2009 Apr; 27(10):1592-9. PubMed ID: 19237629
[TBL] [Abstract] [Full Text] [Related]
20. pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
[TBL] [Abstract] [Full Text] [Related]
[Next]
